Acute Kidney Injury in Lymphoma: A Single Centre Experience

Table 1

Demographic characteristics of study population (𝑛=365).

Age, years, mean ± SD	50.3 ± 16.3
Gender, number (% )
Male	262 (71.8)
Female	103 (28.2)
Lymphoma, number (%)
HL (Hodgkin lymphoma)	87 (23.8)
NHL (non-Hodgkin lymphoma)	278 (76.2)
Mechanical ventilation, number (%)	23 (6.3)
Vasopressors, number (%)	31 (8.5)
Diuretics, number (%)	40 (11)
Vancomycin, number (%)	34 (9.3)
Amphotericin B, number (%)	16 (4.4)
Aminoglycosides, number (%)	14 (3.8)
Median baseline creatinine	0.8 (0.4–11.1)
Median (range) length of stay	2 (0–45)
Renal replacement therapy (%)	12 (3.3)
Tumor lysis syndrome (%)	28 (7.7)
Sepsis	64 (17.5)
AKI	116 (31.8)
	AKI stage 1 = 78 (67.2%)
	AKI stage 2 = 25 (21.6%)
	Aki stage 3 = 13 (11.2%)
Mortality (%)	34 (9.3%)